Oral solids · Contract manufacturing in India

Bacillus Mesentericus TO-A 2 million, Cefixime 200 mg, Clostridium Butyricum TO-A 4 million, Lactic Acid Bacillus 100 million, Streptococcus Faecalis TO-110 60 million Hard-gelatin capsules

Request manufacturing feasibility

Discuss third-party manufacturing of Bacillus Mesentericus TO-A 2 million, Cefixime 200 mg, Clostridium Butyricum TO-A 4 million, Lactic Acid Bacillus 100 million, Streptococcus Faecalis TO-110 60 million Hard-gelatin capsules with Walter Healthcare, India. Share your target market, required capsule count and finished-pack count, packaging and launch timeline for a product-specific quotation.

Catalogue reference
WH-5931
Composition and strength
Bacillus Mesentericus TO-A 2 million, Cefixime 200 mg, Clostridium Butyricum TO-A 4 million, Lactic Acid Bacillus 100 million, Streptococcus Faecalis TO-110 60 million
Dosage form
Hard-gelatin capsules
Indicative administration route
Oral
Therapeutic navigation area
Anti-infectives
Pharmacological class
Cephalosporin antibiotic + Probiotic / prebiotic
Manufacturing stream
Beta-lactam

Catalogue details support an initial B2B discussion. Walter confirms the applicable unit, current licence scope, formula, target market and commercial feasibility before making a commitment.

Clinical reference

Mechanism and pharmacokinetics.

Explore the published evidence for the ingredients in Bacillus Mesentericus TO-A 2 million, Cefixime 200 mg, Clostridium Butyricum TO-A 4 million, Lactic Acid Bacillus 100 million, Streptococcus Faecalis TO-110 60 million Hard-gelatin capsules. Each reference identifies its source formulation and study context. Ingredient studies describe the named reference product; they do not establish the pharmacokinetics, clinical suitability or bioequivalence of this finished formulation.

How to read our product information and sources ↗

Additional ingredient references still to be verified: Bacillus Mesentericus TO-A; Clostridium Butyricum TO-A; Lactic Acid Bacillus; Streptococcus Faecalis TO-110. The references below cover only the named ingredients.

Prescribing-label excerpts

Cefixime

Reference for: Cefixime. Source presentation: capsule; powder, for suspension. Source route: oral.

Mechanism of action

Cefixime is a semisynthetic cephalosporin antibacterial drug [see Microbiology (12.4)].

Pharmacokinetics

Cefixime tablets and cefixime for oral suspension, given orally, are about 40% to 50% absorbed whether administered with or without food; however, time to maximal absorption is increased approximately 0.8 hours when administered with food. A single 200 mg tablet of cefixime produces an average peak serum concentration of approximately 2 mcg/mL (range 1 to 4 mcg/mL); a single 400 mg tablet produces an average peak concentration of approximately 3.7 mcg/mL (range 1.3 to 7.7 mcg/mL). The cefixime oral suspension produces average peak concentrations approximately 25% to 50% higher than the tablets, when tested in normal adult volunteers. Two hundred and 400 mg doses of cefixime oral suspension produce average peak concentrations of 3 mcg/mL (range 1 to 4.5 mcg/mL) and 4.6 mcg/mL (range 1.9 to 7.7 mcg/mL), respectively, when tested in normal adult volunteers. The area under the time versus concentration curve (AUC) is greater by approximately 10% to 25% with the cefixime for oral suspension than with the tablet after doses of 100 to 400 mg, when tested in normal adult volunteers. This increased absorption should be taken into consideration if the cefixime for oral suspension is to be substituted for the tablet. Because of the lack of bioequivalence, cefixime tablets should not be substituted for cefixime for oral suspension in the treatment of otitis media [see Dosage and Administration (2)]. Cross-over studies of tablet versus suspension have not been performed in children.

The 400 mg cefixime capsule is bioequivalent to the 400 mg cefixime tablet under fasting conditions. However, food reduces the absorption following administration of the capsule by approximately 15% based on AUC and 25% based on Cmax.

Peak serum concentrations occur between 2 and 6 hours following oral administration of a single 200 mg tablet, a single 400 mg cefixime tablet or 400 mg of cefixime for oral suspension. Peak serum concentrations occur between 2 and 5 hours following a single administration of 200 mg of cefixime for oral suspension. Peak serum concentrations occur between 3 and 8 hours following oral administration of a single 400 mg cefixime capsule.

Distribution — Serum protein binding is concentration independent with a bound fraction of approximately 65%. In a multiple dose study conducted with a research formulation which is less bioavailable than the cefixime tablet or cefixime for oral suspension, there was little accumulation of drug in serum or urine after dosing for 14 days. Adequate data on CSF levels of cefixime are not available.

Metabolism and Excretion — There is no evidence of metabolism of cefixime in vivo. Approximately 50% of the absorbed dose is excreted unchanged in the urine in 24 hours. In animal studies, it was noted that cefixime is also excreted in the bile in excess of 10% of the administered dose. The serum half-life of cefixime in healthy subjects is independent of dosage form and averages 3 to 4 hours but may range up to 9 hours in some normal volunteers.

Specific Populations — Geriatric Patients: Average AUCs at steady state in elderly patients are approximately 40% higher than average AUCs in other healthy adults. Differences in the pharmacokinetic parameters between 12 young and 12 elderly subjects who received 400 mg of cefixime once daily for 5 days are summarized as follows:

However, these increases were not clinically significant [see Dosage and Administration (2)].

Patients with Renal Impairment: In subjects with moderate impairment of renal function (20 to 40 mL/min creatinine clearance), the average serum half-life of cefixime is prolonged to 6.4 hours. In severe renal impairment (5 to 20 mL/min creatinine clearance), the half-life increased to an average of 11.5 hours. The drug is not cleared significantly from the blood by hemodialysis or peritoneal dialysis. However, a study indicated that with doses of 400 mg of cefixime, patients undergoing hemodialysis have similar blood profiles as subjects with creatinine clearances of 21 to 60 mL/min.

Selected passages from the cited U.S. prescribing label. The studies concern the source product and populations named in each passage; they do not establish Walter-product bioequivalence, an approved indication, or the kinetics of another fixed combination. Tables and the full prescribing information remain available in the source.

Source: DailyMed: Cefixime — capsule, powder, for suspension

Reference accessed . Label revision: 2025-10-14.

Editorial development perspective

What deserves attention in this formulation.

These notes use the catalogue composition and presentation to frame a technical discussion. They are planning considerations, not tested properties or clinical findings for this product.

The clinical references on this page cover only their named ingredients. These development notes do not resolve the remaining clinical-reference gaps.

About these development notes and source limitations ↗

Develop the fill and capsule shell together

Listed presentation: Hard-gelatin capsules.

Review the proposed fill density and flow alongside capsule size, fill-weight consistency and shell compatibility. If granules or pellets are proposed, define their role before choosing the filling process. A capsule size selected from fill weight alone can overlook the behaviour of the actual blend and its storage requirements.

Put organism identity and viability first

Catalogue wording: “Bacillus”.

Ask for the organism and strain identifiers, the method used to measure viable content, and whether the declared count applies at manufacture or through shelf life. In a mixture, clarify the amount assigned to each organism. Assess viability with the proposed process, accompanying ingredients and pack; a total count alone does not describe the complete formulation.

Resolve the amount-per-container or concentration basis

Strength expressions in this entry include “2 million”, “200 mg”, “4 million”, “100 million”, “60 million”.

Clarify whether each stated amount applies to a complete container, a defined volume or a defined weight. Put the agreed denominator beside the ingredient quantity before comparing formula costs or designing a label. Keep the finished fill size as a separate field so that changing the pack does not silently change the intended specification.

Suggested starting point

A practical starting point is to put organism identity and viability first. For this hard-gelatin capsules brief, agree the target characteristics and a short set of measurable development questions before comparing prototypes or supplier proposals. Keep unresolved clinical claims outside the product specification until supporting evidence is available.

Discuss this product brief

Manufacturing & packaging brief

Plan the hard-capsule presentation.

Use this preparation guide for Bacillus Mesentericus TO-A 2 million, Cefixime 200 mg, Clostridium Butyricum TO-A 4 million, Lactic Acid Bacillus 100 million, Streptococcus Faecalis TO-110 60 million Hard-gelatin capsules. These are the decisions to resolve with the technical team before a site, process and commercial scope are confirmed.

Presentation & formulation

Confirm the fill type, shell material, capsule size and printing requirements. Distinguish powder, granule and pellet fills where relevant to the proposed formulation.

Quality & technical transfer

Request review of the fill specification, shell compatibility, analytical methods and applicable release testing. Identify any established formula or transfer package.

Review the technical documents

Packaging configuration

Specify capsules per blister or bottle, the proposed barrier material and carton configuration. Include shell and print requirements in the quotation scope.

Explore packaging options

Details to confirm for this record

Full composition
Keep all named components and their individual amounts together in the specification. Ingredient substitutions, omissions and changed ratios require a separate formula and permission review.
Concentration and pack size
The record does not state a complete concentration basis. Confirm the amount per volume or weight before a specification, label or quotation is finalised; no denominator has been assumed here.
Manufacturing stream
The catalogue assigns this record to the beta-lactam stream. Request review of the proposed unit, product-family scope and applicable segregation arrangements before selecting a manufacturing site.

Quantities, MOQ & lead time

For Bacillus Mesentericus TO-A 2 million, Cefixime 200 mg, Clostridium Butyricum TO-A 4 million, Lactic Acid Bacillus 100 million, Streptococcus Faecalis TO-110 60 million Hard-gelatin capsules (WH-5931), state the capsule count and finished-pack count, target market and reorder forecast. MOQ and lead time depend on the assessed formula, process, components, testing and project readiness; request those terms in writing.

Discuss this manufacturing brief

Explore the context

Build the right manufacturing brief.

Common questions

Before you request a quotation.

Bacillus Mesentericus TO-A 2 million, Cefixime 200 mg, Clostridium Butyricum TO-A 4 million, Lactic Acid Bacillus 100 million, Streptococcus Faecalis TO-110 60 million Hard-gelatin capsules

What is listed in the catalogue?

The catalogue lists Bacillus Mesentericus TO-A 2 million, Cefixime 200 mg, Clostridium Butyricum TO-A 4 million, Lactic Acid Bacillus 100 million, Streptococcus Faecalis TO-110 60 million as hard-gelatin capsules in its anti-infectives navigation area and beta-lactam manufacturing stream.

How do you confirm manufacturing availability?

Send Walter your requirement for Bacillus Mesentericus TO-A 2 million, Cefixime 200 mg, Clostridium Butyricum TO-A 4 million, Lactic Acid Bacillus 100 million, Streptococcus Faecalis TO-110 60 million Hard-gelatin capsules. The team reviews the applicable product permission and unit, formulation and equipment fit, testing, packaging and production schedule before confirming the manufacturing scope in writing. Request the relevant product and facility documents with your enquiry.

What do I need for a quotation?

Share the exact composition and strength, hard-gelatin capsules presentation, target market, initial quantity, preferred pack and timing. Identify whether this is a new product, development brief or transfer.

The quotation must confirm MOQ, inclusions, prerequisites and lead time for the proposed product and site.

What is needed for Indian and export markets?

For India, share the intended brand or institutional supply requirement, pack sizes, initial order quantity and artwork needs for Bacillus Mesentericus TO-A 2 million, Cefixime 200 mg, Clostridium Butyricum TO-A 4 million, Lactic Acid Bacillus 100 million, Streptococcus Faecalis TO-110 60 million Hard-gelatin capsules. Confirm the applicable product permission, manufacturing unit and labelling requirements with the team.

For export, identify each destination country, proposed pack, language and registration or dossier requirements. Ask which product-specific quality and stability documents are available. Container compatibility and destination-market requirements need review; a catalogue record does not establish export registration or a shelf-life commitment.

How do I submit my enquiry?

Use the product-specific enquiry button to carry this composition and dosage form into the form. After a successful submission, a receipt reference confirms that your brief has been saved for review. Use the RFQ checklist to prepare the remaining details.

Technical document review

Which documents can I ask Walter to review?

Ask about manufacturing and packing records, specifications, analytical methods, Certificates of Analysis (COA), stability evidence, the Process Validation Protocol (PVP) and Process Validation Report (PVR). The wider checklist below covers supplier qualification, technical transfer and ongoing supply.

View the full document checklist 14 review areas
Site, licence and audit scope
Manufacturing licence, applicable product permissions, GMP certificates, Site Master File, supplier-qualification questionnaire and relevant audit responses.
Manufacturing, packing and batch release
Master Formula Record (MFR), master packing instructions, Batch Manufacturing Record (BMR), Batch Packing Record (BPR), reconciliation and authorised release records.
Process validation and continued verification
Process Validation Protocol (PVP), Process Validation Report (PVR), process performance qualification documents and continued process verification trends.
Equipment, facilities and utilities
Validation Master Plan (VMP), user requirements, DQ/IQ/OQ/PQ records, calibration and maintenance evidence for relevant equipment and utilities.
Cleaning, carryover and hold times
Cleaning Validation Protocol (CVP), Cleaning Validation Report (CVR), residue limits, recovery studies and applicable clean, dirty and process hold-time studies.
Specifications and analytical evidence
Specifications, Method of Analysis (MOA), Standard Testing Procedure (STP), Certificates of Analysis (COA), analytical validation, verification and method-transfer records.
Stability, packaging and transport
Stability protocols/reports, ongoing stability commitments, pack specifications, approved artwork, compatibility and applicable packaging or transport studies.
Development and technology transfer
Development report, technology-transfer protocol/report, gap assessment, control strategy, critical quality attributes and critical process parameters.
Quality reviews, investigations and changes
Product Quality Review (PQR) / Annual Product Review (APR), deviations, CAPA, change control, OOS/OOT trends, complaints, recalls and relevant SOP/training records.
Material suppliers and impurity risks
API/excipient supplier qualification, traceability, material COAs, relevant origin declarations and impurity risk assessments with supporting tests.
Sterile-product evidence, where applicable
Contamination Control Strategy (CCS), media-fill/aseptic simulation reports, sterilisation and filtration validation, environmental monitoring, sterility/endotoxin and container-closure integrity evidence.
Computerised systems and data integrity
Computerised-system validation, access controls, audit-trail review, backup/restore checks and relevant data-integrity procedures.
Market-specific regulatory support
Applicable dossier sections, API master-file/CEP support, bioequivalence or biowaiver evidence and Certificate of a Pharmaceutical Product (CPP/CoPP), where required and available.
Quality agreement and access arrangements
Quality/technical agreement covering responsibilities, release, changes, subcontracting, investigations, complaints, recalls, audits and document access.

Agree the list for the exact product, site, process, pack, market and project stage. QA confirms what exists, applies and may be shared; some records may require an NDA, redaction or controlled review. See document definitions and review guidance.

Important qualification

This B2B catalogue record is not proof of current approval or confirmation that Bacillus Mesentericus TO-A 2 million, Cefixime 200 mg, Clostridium Butyricum TO-A 4 million, Lactic Acid Bacillus 100 million, Streptococcus Faecalis TO-110 60 million Hard-gelatin capsules is available for sale. It is not prescribing information or patient advice. Any Drugs Rules status, current approval, exemption, applicable unit, licence scope, formulation, claims, brand use, destination-market registration and commercial feasibility require documentary verification and Walter's written confirmation. Read the full regulatory disclaimer.

Composition and classification are taken from Walter's product catalogue. The manufacturing guide helps buyers prepare a technical brief. Clinical references, where shown, describe the cited product and study. Manufacturing guide updated .